Dr. Sittampalam has over 23 years of experience in drug discovery and development in the pharmaceutical industry (Eli Lilly & Co, Indianapolis, IN), and served 4 years in academic drug discovery and high-throughput screening as the Deputy Director of the Institute of Advancing Medical Innovations, and was a professor of Pharmacology, Toxicology, & Therapeutics at the University of Kansas Cancer Center. Kansas City, KS (2007-2011).
His current interests are in developing physiologically relevant 3D cellular models for cancer drug discovery, and circulating tumor cells and cancer stem cells as biomarkers. He was a member of NIH RoadMap MLPCN Grants Review Panels (2005-2009) and has served on stem cell research grant review panels in Maryland (MSCRF) and California (CIRM). He is currently the Editor-in-Chief of the Assay Guidance Manual, sponsored by NCATS and NIMH and published as an e-Book on the NCBI website, a division of the National Library of Medicine, editorial board of the Journal of Biomolecular Sciences (2007-present) and the scientific advisory boards of Science Translational Medicine, Science Exchange Inc., and Stemina Biomarker Discovery, Inc.
Learn more about Dr. Sittampalam’s research at PubMed.